Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

MariTide (maridebart cafraglutide) cycle length: what human studies ran

InvestigationalAHuman trial evidence
Short answer: there is no established MariTide (maridebart cafraglutide) cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • MariTide (maridebart cafraglutide) combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established MariTide (maridebart cafraglutide) cycle length?
No. We found no human studies that report a treatment duration for MariTide (maridebart cafraglutide).
What is the longest human study of MariTide (maridebart cafraglutide)?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
MariTide (maridebart cafraglutide) dosing reference Full research page

References

  1. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial N Engl J Med. 2025
  2. Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial (correspondence) N Engl J Med. 2025
  3. Once-Monthly Maridebart Cafraglutide in Obesity - A Phase 2 Trial. Reply N Engl J Med. 2025
  4. Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications Antib Ther. 2026
  5. Bidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries Peptides. 2026
  6. Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity J Med Chem. 2026
  7. Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity (NCT04478708) ClinicalTrials.gov. 2026
  8. Drugs@FDA application data queried through openFDA for maridebart cafraglutide (no matching application record returned on 24 October 2026) openFDA / Drugs@FDA. 2026
  9. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (NCT07037433) ClinicalTrials.gov. 2026
  10. Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus and Overweight or Obesity (NCT06858878) ClinicalTrials.gov. 2026
  11. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (NCT07037459) ClinicalTrials.gov. 2026
  12. One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy Appetite. 2026
  13. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026